Patents by Inventor Courtney BEERS

Courtney BEERS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS WITH AN ANTI HUMAN CD39 ANTIBODY, AN ANTI HUMAN PD-1 ANTIBODY, AND CHEMOTHERAPY IN GASTRIC CANCER
    Publication number: 20240150487
    Abstract: Provided herein are dosing and combination therapies with a CD39 antibody, a PD-1 antibody, and FOLFOX or CAPDX in gastric cancer.
    Type: Application
    Filed: March 6, 2023
    Publication date: May 9, 2024
    Inventors: Joyson Karakunnel, Achim Moesta, Courtney Beers, Alana Lerner, Benjamin Engelhardt, Akshanth R. Polepally, Daniel E.H. Afar, Peter S. Moon
  • COMBINATION THERAPY INVOLVING ANTI-CD39 ANTIBODIES AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODIES
    Publication number: 20230242660
    Abstract: Provided herein are combination therapies involving antibodies with binding specificity for CD39 and antibodies with binding specificity for PD-1 and/or PD-L1.
    Type: Application
    Filed: February 21, 2020
    Publication date: August 3, 2023
    Inventors: Courtney BEERS, Achim MOESTA
  • BISPECIFIC IMMUNE CELL ENGAGERS WITH BINDING SPECIFICITY FOR HLA-G AND ANOTHER ANTIGEN
    Publication number: 20230235064
    Abstract: Provided herein are bispecific immune cell engagers with binding specificity for HLA-G and an additional antigen, including pharmaceutical compositions, diagnostic compositions, and kits.
    Type: Application
    Filed: June 10, 2021
    Publication date: July 27, 2023
    Inventors: Courtney Beers, Ling-Hon Matthew Chu, Doug Hodges, Christina M. Kochel
  • COMBINATION THERAPY INVOLVING ANTI-CD39 ANTIBODIES AND ADOPTIVE CELL THERAPY
    Publication number: 20230158072
    Abstract: Provided is an antibody combination therapy with an anti-CD39 antibody and an adoptive cell therapy.
    Type: Application
    Filed: April 2, 2021
    Publication date: May 25, 2023
    Inventors: Courtney Beers, Achim Moesta, Nicole Malandro
  • Anti-TIGIT Antibodies
    Publication number: 20230134375
    Abstract: Isolated antibodies or antigen-binding portions that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody or antigen-binding portion thereof has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT.
    Type: Application
    Filed: June 29, 2022
    Publication date: May 4, 2023
    Applicant: Seagen Inc.
    Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz
  • Anti-TIGIT Antibodies
    Publication number: 20230050440
    Abstract: Isolated antibodies that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT. In some embodiments, the antibodies are afucosylated.
    Type: Application
    Filed: June 10, 2022
    Publication date: February 16, 2023
    Applicant: Seagen Inc.
    Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz, Shyra Gardai
  • ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES
    Publication number: 20220372163
    Abstract: Provided herein are antibodies that selectively bind to CD39 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
    Type: Application
    Filed: May 30, 2022
    Publication date: November 24, 2022
    Applicant: TRISHULA THERAPEUTICS, INC.
    Inventors: Vanessa SOROS, Maria KOVALENKO, John CORBIN, Courtney BEERS, Paul Fredrick WIDBOOM, Joseph Robert WARFIELD
  • ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES
    Publication number: 20220340680
    Abstract: Provided herein are antibodies with binding specificity for CD39 and compositions comprising the antibodies, including pharmaceutical compositions, diagnostic compositions and kits. Also provided are methods of using anti-CD39 antibodies for therapeutic and diagnostic purposes.
    Type: Application
    Filed: April 20, 2022
    Publication date: October 27, 2022
    Inventors: Vanessa Soros, Maria Kovalenko, John Corbin, Courtney Beers, Paul Fredrick Widboom, Joseph Robert Warfield
  • Anti-TIGIT antibodies
    Patent number: 11401339
    Abstract: Isolated antibodies that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT. In some embodiments, the antibodies are afucosylated.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: August 2, 2022
    Assignee: Seagen Inc.
    Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz, Shyra Gardai
  • Anti-CD39 antibodies
    Patent number: 11345757
    Abstract: Provided herein are antibodies that selectively bind to CD39 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: May 31, 2022
    Assignee: Trishula Therapeutics, Inc.
    Inventors: Vanessa Soros, Maria Kovalenko, John Corbin, Courtney Beers, Paul Fredrick Widboom, Joseph Robert Warfield
  • ANTI-HLA-G ANTIBODIES, COMPOSITIONS COMPRISING ANTI-HLA-G ANTIBODIES AND METHODS OF USING ANTI-HLA-G ANTIBODIES
    Publication number: 20220135689
    Abstract: Provided herein are antibodies that selectively bind to HLA-G and and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
    Type: Application
    Filed: November 18, 2021
    Publication date: May 5, 2022
    Inventors: Courtney Beers, John Corbin, Doug Hodges, Achim Moesta, Vanessa Soros, Paul Fredrick Widboom, Joseph Robert Warfield
  • ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES
    Publication number: 20210403593
    Abstract: Provided herein are antibodies that selectively bind to CD39 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
    Type: Application
    Filed: September 7, 2021
    Publication date: December 30, 2021
    Inventors: Vanessa Soros, Maria Kovalenko, John Corbin, Courtney Beers, Paul Fredrick Widboom, Joseph Robert Warfield
  • Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies
    Patent number: 11208487
    Abstract: Provided herein are antibodies that selectively bind to HLA-G and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: December 28, 2021
    Assignee: Tizona Therapeutics
    Inventors: Courtney Beers, John Corbin, Doug Hodges, Achim Moesta, Vanessa Soros, Paul Fredrick Widboom, Joseph Robert Warfield
  • ANTI-HLA-G ANTIBODIES, COMPOSITIONS COMPRISING ANTI-HLA-G ANTIBODIES AND METHODS OF USING ANTI-HLA-G ANTIBODIES
    Publication number: 20210340259
    Abstract: Provided herein are antibodies that selectively bind to HLA-G and and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
    Type: Application
    Filed: September 26, 2019
    Publication date: November 4, 2021
    Inventors: Courtney Beers, John Corbin, Doug Hodges, Achim Moesta, Vanessa Soros, Paul Fredrick Widboom, Joseph Robert Warfield
  • Anti-TIGIT Antibodies
    Publication number: 20210269527
    Abstract: Isolated antibodies or antigen-binding portions that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody or antigen-binding portion thereof has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT.
    Type: Application
    Filed: October 28, 2020
    Publication date: September 2, 2021
    Applicant: Seagen Inc.
    Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz
  • ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES
    Publication number: 20210009708
    Abstract: Provided herein are antibodies that selectively bind to CD39 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
    Type: Application
    Filed: July 30, 2018
    Publication date: January 14, 2021
    Inventors: Vanessa SOROS, Maria KOVALENKO, John CORBIN, Courtney BEERS, Paul Fredrick WIDBOOM, Joseph Robert WARFIELD
  • ANTI-HLA-G ANTIBODIES, COMPOSITIONS COMPRISING ANTI-HLA-G ANTIBODIES AND METHODS OF USING ANTI-HLA-G ANTIBODIES
    Publication number: 20200102390
    Abstract: Provided herein are antibodies that selectively bind to HLA-G and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
    Type: Application
    Filed: September 26, 2019
    Publication date: April 2, 2020
    Inventors: Courtney Beers, John Corbin, Doug Hodges, Achim Moesta, Vanessa Soros, Paul Fredrick Widboom, Joseph Robert Warfield
  • Anti-TIGIT Antibodies
    Publication number: 20200062859
    Abstract: Isolated antibodies that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT. In some embodiments, the antibodies are afucosylated.
    Type: Application
    Filed: August 22, 2019
    Publication date: February 27, 2020
    Applicant: Seattle Genetics, Inc.
    Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz, Shyra Gardai
  • Anti-TIGIT Antibodies
    Publication number: 20200040082
    Abstract: Isolated antibodies or antigen-binding portions that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody or antigen-binding portion thereof has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT.
    Type: Application
    Filed: August 15, 2019
    Publication date: February 6, 2020
    Applicant: Seattle Genetics, Inc.
    Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz
  • USE OF ONCOLYTIC VIRUSES, ALONE OR IN COMBINATION WITH A CHECKPOINT INHIBITOR, FOR THE TREATMENT OF CANCER
    Publication number: 20200009204
    Abstract: The present invention relates to the use of oncolytic viruses (e.g., talimogene laherparepvec), either alone or in combination with immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1, and anti-PD-L1 compounds such an antibodies) for the treatment of various types of cancer. In addition, the present invention relates to compositions and kits relating to such uses of oncolytic viruses, either alone or in combination with immune checkpoint inhibitors.
    Type: Application
    Filed: March 14, 2018
    Publication date: January 9, 2020
    Inventors: Pedro J. BELTRAN, Courtney BEERS, Keegan COOKE